Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants May 26, 2020 4:05pm EDT
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress May 26, 2020 7:00am EDT
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress May 19, 2020 8:30am EDT
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) May 18, 2020 4:30pm EDT
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020 May 15, 2020 9:38am EDT
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development May 14, 2020 4:05pm EDT
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors May 11, 2020 4:01pm EDT
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress May 06, 2020 4:01pm EDT
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020 Apr 30, 2020 4:01pm EDT
